USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SEPRACOR, INC.
Address:
SEPRACOR INC
Marlborough, MA 01752
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $514,773.00 8
SBIR Phase II $1,488,996.00 4

Award List:

EXTRACORPOREAL REMOVAL OF LDL WITH IMMOBILIZED ENZYMES

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Stephen L Matson , Principal Investigator
Abstract:
N/a

STEREOCHEMICAL PURIFICATION OF AN ANTI-INFLAMMATORY DRUG IN AN ENZYME MEMBRANE REACTOR

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$40,000.00
Agency:
NSF
Principal Investigator:
Abstract:
N/a

EXTRACORPOREAL REMOVAL OF LDL WITH IMMOBILIZED ENZYMES

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$404,000.00
Agency:
HHS
Principal Investigator:
Stephen L Matson , Principal Investigator
Abstract:
Familial hypercholesterolemia is an inherited disorder that results in high serum cholesterol levels attributable to an elevated level of cholesterol-carrying low-density lipo- protein (ldl). this condition leads to deposition of ldl- derived cholesterol in several tissues, especially tendons and… More

STEREOCHEMICAL PURIFICATION OF AN ANTI-INFLAMMATORY DRUG IN AN ENZYME MEMBRANE REACTOR

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$212,000.00
Agency:
NSF
Principal Investigator:
Abstract:
Enzymatic resolution is a potentially powerful approach to the separation of stereoisomers, and lipases and carboxylesterases are among the more attractive and extensively studied enzymes for this purpose. many lipase substrates -- and many complex molecules with chiral centers -- are poorly soluble… More

AFFINITY MEMBRANE DEVICE FOR SELECTIVE CELL SEPARATIONS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The proposed program is designed to demonstrate the feasibility of a superior, highly controllable and productive affinity membrane device and process for the high-resolution separation of particular cell subsets from complex biological fluids. cell separation is accomplished by expoliting highly… More

MEMBRANE IMMUNOAFFINITY PURIFICATION OF FACTOR VIII:C

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

MEMBRANE IMMUNOAFFINITY PURIFICATION OF FACTOR VIII:C

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$341,220.00
Agency:
HHS
Principal Investigator:
Abstract:
Hemophilia a is an inherited bleeding disorder that stems from lack of coagulation factor viii:c (f.viii:c). crude preparations of plasma-derived factor viii used in treatmentof hemophilia are in short supply worldwide and carry the risk of viral disease transmission. although ultrapurified f.viii:c… More

AN AUTOMATED MEMBRANE SYSTEM FOR RAPID SYNTHESIS AND PURIFICATION OF SHORT HALF-LIFE RADIOPHARMACEUTICALS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,600.00
Agency:
DOE
Principal Investigator:
Abstract:
The objective of this research project is to establish the technical feasibility of an automated process for the enzymatic synthesis and subsequent purification of radiopharmaceuticals -- in particular, of carbon-11 thymidine and thymidine analogs such as azt. our approach is based on the use of… More

Yeast Selection of Drug Resistant HIV Protease Variants

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$97,279.00
Agency:
HHS
Principal Investigator:
Laurence Melnick
Abstract:
N/a

Yeast Selection of Drug Resistant HIV Protease Variants

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$531,776.00
Agency:
HHS
Principal Investigator:
Laurence Melnick
Abstract:
The therapeutic effects of drugs against HIV are overcome by drug resistant HIV variants. We descridrug resistance 'trap' for discovery by rapid positive selection of drug resistant HIV protease variadaptation of the yeast interaction trap/two hybrid system (Brent and Ptashne, Cell 43: 729;… More

PHENOTYPIC ASSAY FOR DRUG SENSITIVITY OF HIV PROTEASES

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$98,279.00
Agency:
HHS
Principal Investigator:
Jones, steven w
Abstract:
N/a

DRUG RESISTANCE CONFERRING MUTATIONS IN HCV N53 PROTEASE

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$79,615.00
Agency:
HHS
Principal Investigator:
Jones, Steven W
Abstract:
N/a